The U.S. government and individual states continue to aggressively pursue healthcare reform, which includes ongoing attempts to manage utilization as well as control and/or lower the cost of prescription drugs and biologics. Recent years have seen a number of reform initiatives focused on drug pricing and payment. For example, the Inflation Reduction Act (“IRA”), passed in 2022, has had and will likely continue to have a significant impact on the pharmaceutical industry.
All entries for: Neurological Diseases
August 3, 2026
Jazz Pharmaceuticals plc
Negative Outlook
Dublin, Ireland
1,000-5,000 employees
The IRA also made several changes to the Medicare Part D benefit, including a limit on annual out-of-pocket costs and a change in manufacturer liability under the program, that could negatively affect our business and financial condition.
Disease Area: Multiple, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
August 3, 2026
Stoke Therapeutics, Inc.
Neutral Outlook
Bedford, MA
201-500 employees
Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.
Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule
August 3, 2026
Design Therapeutics, Inc.
Negative Outlook
Carlsbad, CA
51-200 employees
For example, the Inflation Reduction Act (IRA) passed by Congress authorizes the Secretary of the Department of HHS to negotiate prices directly with participating manufacturers for selected medicines covered by Medicare even if these medicines are protected by an existing patent… This could compromise the confidentiality of our trade secrets and know-how or facilitate third-party efforts to design around or challenge the validity, enforceability, or scope of our patents, or accelerate the development of generics or biosimilars. If we are required to modify or limit the information shared with the FDA to mitigate such risks, it could increase costs, slow our regulatory interactions, or delay product approval timelines.
Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule
July 29, 2026
Dyne Therapeutics
Neutral Outlook
Waltham, MA
201-500 employees
We expect that litigation involving these provisions of the IRA will continue, with unpredictable and uncertain results. Accordingly, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, if approved, any of which could adversely affect our business, results of operations and financial condition.
Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule
July 29, 2026
Biogen Inc
Neutral Outlook
Cambridge, MA
5,001-10,000 employees
Drug prices are under significant scrutiny in the markets in which our products are prescribed; for example the IRA has certain provisions related to drug pricing, including the ability for the U.S. government to set prices for certain drugs in Medicare. We expect drug pricing and other healthcare costs will continue to be subject to political and societal pressures on a global basis. As the policy environment remains dynamic, we will continue to monitor how uncertainty with respect to how the U.S. and foreign tariffs and the U.S. and international pricing may impact our business in the future.
Disease Area: Immune Diseases, Multiple, Neurological Diseases, Psychiatry, Rare Diseases
Drug Type: Biologic, Small Molecule
July 8, 2026
Novartis
Layoffs
Basel, Baselstadt
10,000+ employees
“In its largest layoff round this year, Novartis is cutting its East Hanover, New Jersey, workforce for a fourth time, letting go of 322 employees and bringing the site’s total to 572. The cuts take effect Oct. 2, per a WARN Act notice.
The first three rounds at the Swiss pharma’s East Hanover site were disclosed in March, April and May, affecting 114, 60 and 76 employees respectively. All are effective this year.
In total, Novartis has announced or disclosed at least 792 job cuts in 2026. In May, the company confirmed to BioSpace it was laying off a select number of staff in its biomedical research arm. That same month, it announced the closure of a production site in Wehr, Germany by the end of 2028, eliminating 220 jobs.”
Disease Area: Cardiology, Dermatology, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
May 27, 2026
Johnson & Johnson
Layoffs
New Brunswick, NJ
10,000+ employees
New Jersey’s job market is taking another hit, this time from pharma giant Johnson & Johnson, which is parting ways with 56 employees in New Brunswick, according to a Worker Adjustment and Retraining Notification (WARN) Act posting for the state. The layoffs will take effect on August 21.
This is J&J’s first announced workforce reduction of this year, according to a tally by BioSpace. But the pharma has for years been constantly reshaping its business to accommodate the loss of exclusivity of its autoimmune disease powerhouse Stelara—a campaign that has involved cutting back investments in other parts of its business, while putting more money into higher-value areas like cancer.
Other Big Pharma players to recently slash their New Jersey headcounts include Novartis, Bristol Myers Squibb and Novo Nordisk.
Disease Area: Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule